

UC Davis

UC Davis Previously Published Works

Title

Impact of psychosis risk identification: Examining predictors of how youth view themselves.

Permalink

<https://escholarship.org/uc/item/0s0446cc>

Authors

Yang, Lawrence
Woodberry, Kristen
Link, Bruce
[et al.](#)

Publication Date

2019-06-01

DOI

10.1016/j.schres.2019.01.037

Peer reviewed



Published in final edited form as:

Schizophr Res. 2019 June ; 208: 300–307. doi:10.1016/j.schres.2019.01.037.

Impact of “Psychosis Risk” Identification: Examining Predictors of How Youth View Themselves

Lawrence H. Yang, Ph.D.^{1,2}, Kristen A. Woodberry, Ph.D.^{3,4,5,6}, Bruce G. Link, Ph.D.⁷, Cheryl M. Corcoran, M.D.^{8,9}, Caitlin Bryant, B.A.^{4,10}, Daniel I. Shapiro, Ph.D.^{4,5,6}, Donna Downing, M.S.³, Ragy R. Girgis, M.D.^{11,12}, Gary Brucato, Ph.D.^{11,12}, Debbie Huang, MPH.², Francesca M. Crump, M.A.¹², Mary Verdi³, William R. McFarlane, M.D.^{*,3,13}, Larry J. Seidman, Ph.D.^{*,4,5,6}

¹New York University College of Global Public Health, 715 Broadway, New York, NY 10003.

²Mailman School of Public Health, Columbia University. 722 W 168th St, New York, NY 10032

³Maine Medical Center Research Institute, Portland Maine 04102

⁴Commonwealth Research Center (CRC), Beth Israel Deaconess Medical Center (BIDMC), Boston, MA 02115, USA

⁵Beth Israel Deaconess Medical Center (BIDMC), Boston, MA 02115, USA

⁶Harvard Medical School, Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA

⁷University of California at Riverside, 900 University Ave, Riverside, CA 92521

⁸Icahn School of Medicine at Mount Sinai, Department of Psychiatry, 1 Gustave L. Levy Pl., New York, NY 10029

⁹Mental Illness Research, Education, and Clinical Center (MIRECC VISN 2), James J. Peter Veterans Affairs Medical Center, 130 West Kingsbridge Rd, Bronx, NY, 10468, USA

¹⁰University of Massachusetts, Boston, 100 Morrissey Boulevard, Boston, MA 02125

¹¹New York State Psychiatric Institute, Columbia University Department of Psychiatry, 1051 Riverside Dr. New York, NY 10032

Corresponding author: Lawrence H. Yang, Ph.D. New York University College of Global Public Health, New York, NY 10003. Lawrence.yang@nyu.edu telephone number: 212-992-6334.

*Joint senior authorship

Contributors

LHY, LS, WM, CC and BGL designed the study.

KW, DS, DD, and RG coordinated the study.

CB, DD, GB, and FMC collected the data.

DH and LHY analyzed the data, and LHY, KW, BGL, CC, LS, and WM interpreted the data. FMC conducted the literature search.

LHY and KW wrote the first draft, and BGL, CC, LS and WM commented on and edited the manuscript for intellectual content.

All authors reviewed the manuscript for important intellectual content and approved the manuscript for publication.

Role of Funding Source

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

¹²The Center of Prevention and Evaluation (COPE), New York State Psychiatric Institute, Columbia University Medical Center, 1051 Riverside Dr., New York, NY 10032

¹³Department of Psychiatry, School of Medicine, Tufts University, 0 Park Plaza #1101, Boston, MA 02116

Abstract

Background: Identifying young people as at clinical high-risk (CHR) for psychosis affords opportunities for intervention to possibly prevent psychosis onset. Yet such CHR identification could plausibly increase stigma. We do not know whether these youth already perceive themselves to be at psychosis-risk (PR) or how their being told they are at PR might impact how they think about themselves.

Methods: 148 CHR youth were asked about labels they had been given by others (labeling by others) or with which they personally identified (self-labeling). They were then asked which had the greatest impact on how they thought about themselves. We evaluated whether being told vs. thinking they were at PR had stronger effects.

Findings: The majority identified nonpsychotic disorders rather than PR labels as having the greatest impact on sense of self (67.6% vs. 27.7%). However, participants who identified themselves as at PR had an 8.8 (95% CI=2.0-39.1) increase in the odds of the PR label having the greatest impact ($p<0.01$). Additionally, having been told by others that they were at PR was associated with a 4.0 increase in odds (95% CI=1.1-15.0) that the PR label had the most impact ($p<0.05$).

Interpretation: Nonpsychotic disorder labels appear to have a greater impact on CHR youth than psychosis-risk labels. However, thinking they are at PR, and, secondarily, being told they are at PR, appears to increase the relative impact of the PR label. Understanding self- and other-labeling may be important to how young people think of themselves, and may inform early intervention strategies.

Funding: NIMH R01-MH096027 (PI:Yang)

Keywords

Clinical high risk state for psychosis; psychosis risk; early intervention; identity; stigma

1. Introduction

Despite emerging evidence that early treatment of mental illness may positively impact illness course and recovery (Fusar-Poli et al., 2013; McFarlane et al., 2015), stigma can prevent those experiencing early signs of mental illness from accessing treatment, cause psychological distress, and disrupt capacity for full recovery (Yang et al, 2010, Corcoran et al., 2005). A vanguard movement is now identifying youth at clinical high-risk (CHR) for psychosis with the aim of altering the course of illness and potentially preventing the onset of an initial episode of psychosis (Yung et al, 2003, Fusar-Poli et al., 2013). Yet identification of CHR youth, and conveying of psychosis-risk (PR) status, has raised questions about what effects communicating this high-risk status may have upon identified

youths' views of themselves. To advance strong preventive measures, public mental health efforts must confront these issues to maximize benefit and minimize harm.

Youth identified as at CHR (henceforth: "CHR youth") are identified via interview (e.g., for this study, the Structured Interview for Psychosis-Risk Syndromes [SIPS]; Miller et al., 2003) predominantly by the presence of new or worsening attenuated psychotic symptoms (e.g., unusual and unfounded concern about being watched) accompanied by distress or impairment (Woodberry et al., 2016). We use "CHR" to refer to the syndrome itself and youth identified by internationally-recognized risk criteria (via the SIPS). It is thus a technical term. We use "psychosis-risk (PR)" to refer to the broad concept of elevated risk for developing psychosis as it might be conveyed or understood by non-researchers.

CHR programs may alleviate stigma through careful clinical practice. This often includes taking a proactive mental health care perspective centered on an individual's or family's specific experiences, values, and understanding of mental health and illness (Friedman-Yakoobian, in press). Conveying PR to youth may bring relief and encourage health-promoting behaviors (Yang et al., 2015). Conversely, conveying PR to youth may activate stigma via an additional psychiatric "label" of PR (Yang et al., 2015; Tsuang et al., 2013), thus eliciting distressing negative stereotypes associated with psychosis (Uttinger et al., 2015). Approximately 30-35% of CHR youth may develop threshold psychosis within 2-2½ years of identification, meaning that a majority thus identified could be exposed to potential stigma for a condition that in some cases will never develop (Fusar-Poli et al., 2012).

Understanding stigma related to CHR identification is complicated by high rates of comorbid, pre-existing diagnoses and prior labeling. The majority (~82%) of identified individuals have had treatment (and thus encountered labeling) for nonpsychotic disorders (e.g., depression or anxiety; Woodberry et al., 2016, McFarlane, et al, 2015). CHR youth are distressed by affective or cognitive symptoms that may themselves elicit burden or exclusion (Cavelti et al., 2014) and are identified with heterogeneous diagnoses (e.g., depression or anxiety, and/or CHR), any of which could have differential ramifications for the future development of distress, stigma, help-seeking or treatment engagement (Moses 2009a, 2009b, Yang et al, 2013). It thus remains unknown to what extent CHR youth identify with pre-existing nonpsychotic conditions, compared with a newly-developing PR status.

1.1 'Labeling by Others' and 'Self-Labeling' Processes

Dual processes of being told that one is at PR (labeling by others) and thinking oneself to be at PR (self-labeling) may be associated with increased sense of stigma and poorer psychological well-being (e.g., among youth with nonpsychotic disorders who think of themselves as "mentally ill"; Moses, 2009a, Moses 2009b). Psychiatric "labeling" by socially-relevant others (Link et al., 1989), including via formal diagnosis by mental health clinicians, may alter youths' views of themselves. Given that PR may be conveyed to youth whose self-views are still developing (Nieman & McGorry, 2015), the impact of being labeled as at PR by others (including mental health professionals, school officials, and relatives; Wisdom & Green, 2004) may have long-lasting effects.

However, youths' identities are not entirely dependent on others telling them they are at PR (see Figure 1). CHR youth may also be affected by their own "self-labeling", or what they have come to believe about themselves through experience or their own meaning-making (Thoits, 1985). Self-labeling with PR may begin when an individual observes and classifies his/her symptomatic experiences as indicators that something is seriously wrong, and that they may be experiencing a form of nascent psychosis. This self-labeling might then lead to a heightened awareness and agreement with societal stereotypes of psychosis (Corrigan et al, 2011). Having a family history of psychosis may further facilitate this (Kim et al, 2017). Private 'self-labeling' of PR status could thus initiate changes in how CHR youth see themselves. No prior research has examined *if, and what, CHR youth label themselves at-risk for*. Further, we do not know the relative impact of self-labeling and other-labeling on a youth's sense of self.

Being told that one is at PR may introduce or reinforce self-labeling as being at PR. Self-labeling may thus partially account for some effects of being labeled by others. Alternatively, being told one is at-risk for PR may impact how one thinks about oneself independent of self-labeling processes. Understanding how these processes impact CHR youth' self-identification is key because changes in sense of self have been linked with stigma, psychological well-being, and mental health service utilization in youth with nonpsychotic illnesses (Moses, 2009a; Moses, 2009b).

Self-labeling and labeling by others also take place within the context of "individualized feedback" by specialized CHR programs, or when the PR status is communicated by specialized CHR clinicians to identified youth (which also might be considered a specialized form of being "labeled by others"). Yet the content and timing of individualized feedback regarding PR status varies across CHR programs by context, clinician, youth, and family (Friedman-Yakobian et al., in press). Further, there currently is no consensus on a standardized feedback procedure for all participants in CHR programs. Specialized CHR program clinicians are typically trained to give individualized feedback based on a wide range of factors, including the individual and family's concerns and treatment engagement, cultural background, and estimated risk within the CHR classification. For example, PR feedback might be adapted according to relatively low level symptoms or the presence of factors associated with reduced risk (e.g., intact cognition, being of older age, having high social functioning, etc.; Cannon et al., 2016). Better understanding of how self-labeling and labeling by others contribute to how CHR youth see themselves could help guide the process of how PR status is conveyed to youth across specialized CHR programs.

1.2 Hypothesis:

We first provide descriptive data by assessing the extent to which CHR youth self-identified as at PR, vs. other non-psychotic labels. Following, given prior literature showing respective effects of both labeling by others and self-labeling, we hypothesized that being told one is at PR, and thinking one is at PR, would each have independent effects on how CHR youth view themselves.

2. Methods

2.1 Procedures

Data are from 148 CHR participants in a study conducted between November 2012 and December 2015 at Beth Israel Deaconess Medical Center/Harvard Medical School (Boston, MA), Maine Medical Center (Portland, ME), and New York State Psychiatric Institute (New York, NY). In conveying PR status, while site clinicians were not trained or instructed to provide uniform PR feedback (following standard practice as described above), PR feedback addressed the risk that the individuals' attenuated psychotic symptoms might worsen, that they were at higher risk of developing a psychotic disorder than their peers, and that being 'at risk' is different than actually 'having developed' a psychotic disorder. The specific language used, timing and spacing (one session or multiple), and nature (oral and/or written) of feedback varied according to clinical judgment and individual factors such as presenting concerns and questions, language capacity, symptom severity, insight, and family cultural values and norms. These variations are common to many CHR clinics and research settings around the world. Thus, in lieu of mandating provision of the exact same information at every site at precisely the same time, we recorded who had been formally told by specialized CHR program staff that they were at PR prior to administration of measures and controlled for it statistically (see "Analyses"). This method reflects what happens naturalistically across sites, across the country, and internationally.

2.2 Subjects and CHR identification procedures

CHR individuals 12-35 years old were recruited from outreach efforts or self-referred in response to media, public transportation, and online advertisements. Some were recruited from specialized clinics or other CHR studies. Participants met criteria for 1 of three CHR syndromes assessed by the SIPS (Version 5.0; Miller et al., 2003). Per SIPS guidelines, the syndromes could not be better accounted for by another psychiatric disorder, including substance use and medical disorders, per careful assessment of symptoms, timelines and syndrome/disorder overlap. Current and lifetime (comorbid) mental disorders were diagnosed according to the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Version IV (SCID-I/P, First et al. 2002). Exclusion criteria included history of psychotic disorder, imminent risk of self-harm/violence, major medical/neurological disorder, or IQ<70. SIPS assessors were masters and doctoral-level clinicians and trainees rigorously-trained by clinicians trained and certified by the official Yale SIPS trainers. Further, SIPS ratings and final CHR classification were confirmed by consensus during conference calls attended by all clinicians across sites.

Written informed consent was obtained from adult participants; minors provided written assent and their parents/guardians provided written informed consent. Consent forms described the study purpose in accordance with IRB requirements and pre-existing standards with this population at each site. All sites' consent forms described possible CHR symptoms (e.g., feeling suspicious of others), with the New York site indicating that participants were at "a somewhat increased risk of psychosis". This study was approved by the Beth Israel Deaconess Medical Center, Maine Medical Center, and New York State Psychiatric Institute

Institutional Review Boards. All participants were referred to mental health treatment if not already receiving it.

2.3 Measures

CHR symptoms and functioning were assessed by clinician interview; all other responses were assessed via self-report by questionnaire or by interview with a BA-level research assistant who had received extensive training in administering the measures.

2.3.1 At-Risk Labeling Module: We queried perceptions of being ‘at-risk’ for five conditions: “depression”, “anxiety”, “bipolar”, “psychosis”, and “schizophrenia.” Figure 2 outlines our three main variables: 1) *Told* (“Has anyone *told* you that you were ‘at-risk for’ or ‘developing’ [condition]?”); 2) *Think* (“Do you *think* you are ‘at-risk for’ or ‘developing’ [condition]?”); 3) *Most impact* (“What [single condition] had the *biggest impact* on how you think of yourself?”). For the *told* variable, the recalled source of labeling was recorded (clinician, school personnel, relative, or friend) when possible; individualized PR feedback delivered by CHR clinicians was tracked separately. Participants responded “Yes/No” to *Told* and *Think* questions for each at-risk condition. For the *most impact* question, respondents identified one at-risk condition only.

2.3.2 CHR Symptoms—The SIPS was used to evaluate positive (five items), negative (six items), disorganized (four items), and general (four items) symptoms (rated 0 [absent] to 6 [severe and psychotic]) (Miller et al., 2003).

2.3.3 Social Functioning—To further characterize the sample, involvement with peers, intimate partners, and relatives was measured by the Global Functioning: Social Scale, and performance in school or work was measured by the Global Functioning: Role Scale (1-10 rating; Cornblatt, et al., 2007).

2.4 Analysis

We calculated frequencies of yes/no responses for the *told* (labeling by others), *think* (self-labeling), and *most impacted* questions for each of the five at-risk categories. Further, responses to being at-risk for “psychosis” or “schizophrenia” were combined into a single “Psychosis Risk” (PR) category, and responses to being at-risk for “depression”, “anxiety” or “bipolar” were combined into a single “Non-Psychotic Disorder” category; McNemar’s test was used to test whether endorsement of PR or Non-psychotic disorders across variables differed significantly. Bivariate associations were examined between: a) “labeling by others” (*told*), b) “self-labeling” (*think*); and c) being *most impacted* by PR (our main outcome, defined as “yes/no”). Second, bivariate associations between receiving individualized PR feedback and having been *told*, *thinking*, and having been *most impacted* by PR were examined. These analyses were repeated stratifying for those who had received “prior individualized PR feedback” and those who had not. Third, to test the association of *told* and *think* responses with PR having the *most impact*, we conducted a series of logistic regressions. In the first model, we entered *told* as a predictor of being “*most impacted*” by PR. To account for whether individuals had been given individualized PR feedback prior to administration of measures, this binary variable was included in the model. In the second

model, family history of psychosis, sociodemographic variables, and CHR symptoms were added. In a third model, *think* was added as a predictor to examine this variable's effect, and to examine whether the effect of *told* was attenuated by the effect of *think*. Finally, to account for site effects, we replaced individualized PR feedback (which covaried highly) with site in a separate set of regressions (Supplementary Table 2). Statistical significance was set at $p < 0.05$ (two-sided).

3. Results

Sociodemographic and Clinical Characteristics

Our sample was comprised of a late adolescent, primarily student, cohort which was approximately 2/3 male and >60% white (Table 1). The majority (>70.3%) met criteria for 1 comorbid disorder, most commonly depressive (50.7%) and anxiety (43.2%) disorders. Of participants, 30.4% had received individualized PR feedback prior to administration of measures, 68.9% of whom were from the New York site. The differing timing of having received individualized PR feedback was due to differences across sites in whether participants could be recruited and assessed *prior to* PR feedback ($n=103$; 88% of participants from the Boston and Maine sites [103/117 total]) or only *after* PR feedback ($n=45$; remaining Boston and Maine participants and all of New York participants; New York participants $n=31$, $M=10.2$, $SD=9.3$ weeks).

3.1 Descriptive Statistics: Labeling by others (told), self-labeling (think), and “most impacted” variables

When examining descriptive statistics, consistently across all labeling and most impacted queries, participants appeared to endorse being “at risk for” or “developing” ‘depression’ and ‘anxiety’ at higher frequencies than ‘psychosis’ and ‘schizophrenia’ and ‘bipolar’ (Table 2A). Statistical comparisons indicated that endorsement of psychosis-risk (i.e., psychosis and schizophrenia) was higher for *told*, *think*, and *most impacted*, when compared with non-psychotic (i.e., depression, anxiety and bipolar) conditions (Table 2B). Only 27.7% identified PR labels as having *most impacted* them.

3.2 Bivariate Associations: Other- and self-labeling and being “most impacted” by PR

When examining bivariate associations, being *told*, *thinking*, and being *most impacted* by PR were all significantly associated with each other (Tables 3 A-B). To check whether these results held for those who had received “prior individualized PR feedback” ($n=45$) and those who had not ($n=103$), Chi-square tests were conducted to probe whether the effect of being *told* or *thinking* one was at PR was significantly associated with being *most impacted* by PR in each subgroup. For both subgroups, Chi-Square tests showed significant effects in the expected direction for both *told* and *think*; i.e., CHR youth who were *told* or *think* they were at PR showed higher proportions of being *most impacted* by PR (all Fisher's Exact Tests $p < 0.05$; see Supplementary Table 1). As expected, having received “individualized PR feedback” prior to administration of measures was also associated with higher proportions of being *told* and *thinking* one was at PR. However, it was not associated with being *most impacted* by PR (Table 3C).

3.3 Logistic Regression: Is labeling by others vs. self-labeling more strongly related with being “most impacted” by PR?

In an initial logistic regression (Table 4; Model 1), having been *told* was associated with an 8.7 increase in odds of being *most impacted* by PR (95% CI=3.1-24.8), with individualized PR *feedback* entered into the regression model. Results for being *told* remained consistent (OR=10.6 [95% CI 3.3-33.9]) after adding family history of psychosis, sociodemographic variables, and CHR symptoms into the model (Model 2). When *think* was added into the model (Model 3), the effect of being *told* was diminished by 68.8% to a 4.0 increase in odds of being *most impacted* by PR (95% CI=1.1-15.0). In that analysis, as expected, *think* was independently associated with an 8.8 increased odds of being *most impacted* by PR (95% CI=2.0-39.1). Finally, results for *think* and *told* remained significant when substituting site for individualized PR feedback (Supplementary Table 2).

4. Discussion

These findings provide new insights into how CHR youth self-identify and the relative impact of the PR label on how they think about themselves shortly after entry into a specialized CHR program. On one hand, only a minority (27.7%) identified the PR label as having more impact than non-psychotic labels (particularly depression and anxiety). Yet we also identified that youth considering themselves to be at PR mattered more than having been *told* they were at PR in the PR label having the most impact. Yet having been *told* one was at PR (e.g., by CHR program or community clinicians, school personnel, or relatives) remained independently associated with a four-fold increased odds of PR having the *most impact*, even after considering the impacts of *thinking* and individualized PR feedback.

Our results help to illuminate findings from another key labeling study of Ultra High-Risk youth (Rüsch et al., 2014a). This study demonstrated that the extent to which individuals self-labeled as “severely mentally ill” was relatively high on average (mean=5.1 [SD=1.8]; 9-point rating scale) following UHR identification, and that self-labeling was significantly associated with appraisal of stigma as harmful. Our results suggest that these youth may identify as “severely mentally ill” based on *nonpsychotic* labels or symptoms (whereby >70% of our participants were co-morbid for 1 non-psychotic disorder) rather than or in addition to psychotic labels or symptoms. Accordingly, nonpsychotic labels (or symptoms) in our study were experienced as conferring more impact than intermittent psychotic-like labels (or symptoms) for over 2/3 (67.6%) of participants at initial CHR identification.

Although additional data, particularly qualitative, are needed to explore why PR appears to be less influential to sense of self at initial PR identification, a number of explanations exist. First, labeling may occur in fairly benign ways, e.g., in a school counselor's office where a student's concerns are heard, and hope is instilled regarding available treatments. Second, the majority of participants were voluntarily help-seeking, and this agency may reduce the salience of psychosis-risk stereotypes. Third, the PR label may be less influential due to the optimism common to adolescence (Elkind, 1967, Moses, 2009a). Fourth, the vast majority (>90%) of CHR youth in preventive clinical trials indeed do not develop a psychotic disorder (Fusar-Poli, et al., 2012; McFarlane, et al., 2015). The impact of the PR label may be attenuated to the degree that these youth intuit this or have this explained to them, as is

standard practice in many CHR programs. Finally, a less influential impact of the PR label could be attributed to heightened stigma towards the PR label (Yang et al, 2013), which could lead CHR youth to endorse it less.

Our findings begin to elucidate how labeling processes—via others' actions (i.e., being *told*) and one's own interpretation of symptomatic experiences (i.e., what one *thinks*)—shape the impact of the PR label. First, because *thinking* oneself to be at PR reduced the effect of being *told*, individuals' self-labeling appears to account in part for the effect of being *told*. However, among those who had not been *told* by others of their PR status (n=62 total), 21% (13/62; see bottom left hand cell, Table 3A) still reported *thinking* they were at PR, thus illustrating how interpretations of one's symptoms remains vital (Ben-David et al., 2014). Second, being *told* about PR remained an independent correlate with one's sense of self after adding *think*, thus indicating that being informed about one's PR status had distinct, albeit smaller, effects. This highlights the need to further understand the relative impact of different aspects of PR labeling, including *who* does the labeling, *what* is actually said, and *how* it is done (e.g., being *told* that one is PR in a derogatory fashion by a peer may have diametrically opposite impacts than being told by a specialized CHR program). Providing accurate education regarding PR has been shown to reduce stigma in community respondents (Yang et al., 2013). Unfortunately, these data cannot speak to the effects of being *told* by a specific source (school personnel, relative, friend, or clinician).

4.1 Limitations and Future Research

Limitations include sampling of voluntary participants who, for the most part, were in or seeking treatment, and who thus may have been less concerned about stigma than nonparticipant CHR youth. Nonetheless, study inclusion was less restrictive (i.e., it did not have typical restrictions for MRI and other biomarker studies) and less burdensome than other CHR studies at these three sites, such that the sampling and descriptive data is likely to be more representative of the true help-seeking CHR population. Further, our assessment of which label had the most impact came from a single-item, precluding assessment of reliability. However, it was an important initial probe of relative impact on sense of self that could elicit follow-up studies examining construct validity with other outcomes (e.g., stigma, help-seeking) in PR youth. Further, because some participants might have thought about how their symptom experience, rather than the label, impacted them in response to being asked what at-risk status had the biggest impact on sense of self, it is important for future research to more clearly separate impact of labels from that of symptoms on how PR youth view themselves. Another limitation is that for participants assessed prior to PR feedback, prior diagnoses of nonpsychotic disorders may have had more impact simply because they were the most salient or only known diagnoses, particularly for individuals who were administered measures before feedback. Due to the cross-sectional design, we cannot determine causality; being '*most impacted*' by PR may shape how individuals recall being *told* of, vs. *thinking* they were at-risk for, this status. We could not ascertain exactly when participants were first *told*, and this variable could be influenced by recall and social desirability bias. The impact of being *told* is likely influenced over time by the subsequent course of symptoms, including natural fluctuations as well as the effects of treatment. Thus, participants who had been *told*, even 1-2 months prior, may find the PR label to have less

group fosters cross-family, non-stigmatizing illness definitions to address stigma (McFarlane et al., 2012), and we are adapting empirically-based stigma interventions (Lucksted et al., 2016) for use at time of conveying of PR status. By informing efforts with our data, we highlight greater attention to perceptions of self and labeling experiences across both PR and non-psychotic diagnoses in the delivery of services.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We would like to thank Emily Kline and Leda Kennedy for their assistance in collecting data at Beth Israel Deaconess Hospital, Anna Cloutier for her assistance in collecting data at Maine Medical Center, Gabriella Dishy for her help in formatting the manuscripts, and Emily He, Bernalyn Ruiz, Jenny Shen, Junko Morita, Lily Kamalyan, Drew Blasco and Margaux Grivel for their assistance in collecting data at New York State Psychiatric Institute/ Columbia Medical Center. We also thank Xinhua Liu for her help with statistical consultation. We finally dedicate this manuscript to beloved friend and collaborator, Larry Seidman.

Conflict of Interest

The authors have declared that there are no conflicts of interest in relation to the subject of this study. We declare that no authors have support from any company for the submitted work. Dr. Yang was supported by funds from NIMH R01-MH096027 (PI: Yang), entitled "Stigma Associated with a High-Risk State for Psychosis", and a Brain and Behavior Foundation Young Investigator Award (NARSAD 17839). Dr. Corcoran was supported by funds from NIMH R01MH107558. Dr. Shapiro reports grants from NIMH (under Dr. Larry Seidman, site PI at BIDMC) during the conduct of the study, and Ms. Huang reports grants from NIMH during the conduct of the study; During the 36 months prior to submission, Dr. Woodberry was supported by funds from NIH (R01 MH096027;R21 MH093294;U01 MH081928; R01 MH101052; K23 MH102358), the Massachusetts Department of Mental Health ("Training for Early Intervention in Psychosis" and SCDMH82101008006), and the Sidney R. Baer, Jr Foundation. Dr. Girgis reports non-financial support from Genentech, grants from Otsuka, non-financial support from Bioadvantex, grants from Allergan, outside the submitted work. Dr. McFarlane was supported by funds from the Maine Medical Center Research Institute.

References

1. Ben-David S, Birnbaum ML, Eilenberg ME, DeVlylder JE, Gill KE, Schienle J, ... & Corcoran CM (2014). The subjective experience of youths at clinically high risk of psychosis: a qualitative study. *Psychiatric Services*, 65(12) 1499–1501. [PubMed: 25179420]
2. Cavelti M, Rüschen N, Vauth R, 2014 Is living with psychosis demoralizing?: Insight, self-stigma, and clinical outcome among people with schizophrenia across 1 year. *The Journal of nervous and mental disease*. 202(7):521–9. [PubMed: 24933416]
3. Corcoran C, Malaspina D, Hercher L, 2005 Prodromal interventions for schizophrenia vulnerability: the risks of being "at risk". *Schizophrenia research*. 73(2): 173–84. [PubMed: 15653260]
4. Corrigan P, Rafacz A, Rüschen N. 2011 Examining a progressive model of self-stigma and its impact on people with serious mental illness. *Psychiatry Research*. 189(3): 339–43. [PubMed: 21715017]
5. Cornblatt BA, Auther AM, Niendam T, Smith CW, Zinberg J, Bearden CE, & Cannon TD (2007). Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia. *Schizophrenia bulletin*, 33(3), 688–702. [PubMed: 17440198]
6. Elkind D (1967). Egocentrism in adolescence. *Child development*, 1025–1034. [PubMed: 5583052]
7. Epstein S, 1973 The self-concept revisited: Or a theory of a theory. *American psychologist*. 28(5):404. [PubMed: 4703058]
8. Falkenberg I, Valmaggia L, Byrnes M, Frascarelli M, Jones C, Rocchetti M, ... & Fusar-Poli P (2015). Why are help-seeking subjects at ultra-high risk for psychosis help-seeking?. *Psychiatry research*, 228(3) 808–815. [PubMed: 26071897]

9. First MB, S., & Gibbon M,W (2002). Structured clinical interview for DSM-IV-TR axis I disorders, research version, patient edition (SCID-I/P). New York: Biometrics Research.
10. Friedman-Yakoobian M, West ML, Woodberry KA, O'Donovan KE, Zimmet S, Gngong-Granato A, Giuliano AJ, Guyer ME, Rodenhiser-Hill J, Keshavan MS, and Seidman LJ. Development of a Boston treatment program for youth at clinical high risk for psychosis: Center for early detection, assessment, and response to risk (CEDAR). *Harvard Review of Psychiatry* (in press).
11. Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, Valmaggia L, Barale F, Caverzasi E, McGuire P, 2012 Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. *Archives of general psychiatry*. 69(3):220–9. [PubMed: 22393215]
12. Fusar-Poli P, Borgwardt S, Bechdolf A, Addington J, Riecher-Rössler A, Schultze-Lutter F, Keshavan M, Wood S, Ruhrmann S, Seidman LJ, Valmaggia L, 2013 The psychosis high-risk state: a comprehensive state-of-the-art review. *JAMA psychiatry*. 70(1): 107–20. [PubMed: 23165428]
13. Hall RC (1995). Global assessment of functioning: a modified scale. *Psychosomatics*, 36(3) 267–275. [PubMed: 7638314]
14. Kim SW, Polari A, Melville F, Moller B, Kim JM, Amminger P, Herrman H, McGorry P, Nelson B (2017). Are current labeling terms suitable for people who are at risk of psychosis? *Schizophrenia research*. 188: 172–77. [PubMed: 28117104]
15. Link BG, Cullen FT, Struening E, Shrout PE, Dohrenwend BP, 1989 A modified labeling theory approach to mental disorders: An empirical assessment. *American sociological review*. 400–23.
16. Lucksted A, Drapalski AL, Brown CH, Wilson C, Charlotte M, Mullane A, & Fang LJ (2016). Outcomes of a psychoeducational intervention to reduce internalized stigma among psychosocial rehabilitation clients. *Psychiatric services*, 68(4) 360–367. [PubMed: 27903136]
17. McFarlane WR, Lynch S, Melton R, 2012 Family psychoeducation in clinical high risk and first-episode psychosis. *Adolescent Psychiatry*. 2(2): 182–94.
18. McFarlane WR, Levin B, Travis L, Lucas FL, Lynch S, Verdi M, Williams D, Adelsheim S, Calkins R, Carter CS, Cornblatt B, 2015 Clinical and functional outcomes after 2 years in the early detection and intervention for the prevention of psychosis multisite effectiveness trial. *Schizophrenia bulletin*. 41 (1):30–43. [PubMed: 25065017]
19. McGorry PD, Tanti C, Stokes R, Hickie IB, Carnell K, Littlefield LK, Moran J, 2007 headspace: Australia's National Youth Mental Health Foundation-where young minds come first. *Med J Aust*. 187(7 Suppl):S68–70. [PubMed: 17908032]
20. Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Ventura J, McFarlane W, Perkins DO, Pearlson GD, Woods SW, 2003 Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. *Schizophrenia bulletin*. 29(4):703. [PubMed: 14989408]
21. Moses T, 2009 Self-labeling and its effects among adolescents diagnosed with mental disorders. *Social science & medicine*, 68(3) 570–578. [PubMed: 19084313]
22. Moses T 2009 Stigma and self-concept among adolescents receiving mental health treatment. *American Journal of Orthopsychiatry*, 79(2) 261. [PubMed: 19485644]
23. Nieman DH, McGorry PD, 2015 Detection and treatment of at-risk mental state for developing a first psychosis: making up the balance. *The Lancet Psychiatry*. 2(9):825–34. [PubMed: 26360901]
24. Rüsçh N, Corrigan PW, Heekeren K, Theodoridou A, Dvorsky D, Metzler S, ... & Rössler W 2014 Well-being among persons at risk of psychosis: the role of self-labeling, shame, and stigma stress. *Psychiatric Services*, 65(4) 483–489. [PubMed: 24382666]
25. Rüsçh N, Müller M, Heekeren K, Theodoridou A, Metzler S, Dvorsky D, Corrigan PW, Walitza S, Rössler W, 2014 Longitudinal course of self-labeling, stigma stress and well-being among young people at risk of psychosis. *Schizophrenia research*. 158(1): 82–4. [PubMed: 25086660]
26. Rüsçh N, Heekeren K, Theodoridou A, Müller M, Corrigan PW, Mayer B, Metzler S, Dvorsky D, Walitza S, Rössler W, 2015 Stigma as a stressor and transition to schizophrenia after one year among young people at risk of psychosis. *Schizophrenia research*. 166(1):43–8. [PubMed: 26036814]
27. Thoits PA, 1985 Self-labeling processes in mental illness: The role of emotional deviance. *American journal of Sociology*. 91(2):221–49.

28. Tsuang MT, Van Os J, Tandon R, Barch DM, Bustillo J, Gaebel W, Gur RE, Heckers S, Malaspina D, Owen MJ, Schultz S, 2013 Attenuated psychosis syndrome in DSM-5. *Schizophrenia research*. 150(1):31–5. [PubMed: 23773295]
29. Uttinger M, Koranyi S, Pappmeyer M, Fend F, Ittig S, Studerus E, Ramyeard A, Simon A, Riecher-Rössler A, 2015 Early detection of psychosis: helpful or stigmatizing experience? A qualitative study. *Early intervention in psychiatry*. 181: 69–82.
30. Wisdom JP, Green CA, 2004 “Being in a funk”: Teens’ efforts to understand their depressive experiences. *Qualitative Health Research*. 14(9): 1227–38. [PubMed: 15448297]
31. Woodberry KA, Seidman LJ, Bryant C, Addington J, Bearden CE, S Cadenhead K, Cannon TD, Cornblatt BA, McGlashan TH, Mathalon DH, Perkins DO, 2016 Treatment precedes positive symptoms in North American adolescent and young adult clinical high risk cohort. *Journal of Clinical Child & Adolescent Psychology*. 1–0. [PubMed: 26743331]
32. Yang LH, Wonpat-Borja AJ, Opler MG, Corcoran CM, 2010 Potential stigma associated with inclusion of the psychosis risk syndrome in the DSM-V: an empirical question. *Schizophrenia research*. 120(1):42–8. [PubMed: 20399610]
33. Yang LH, Anglin DM, Wonpat-Borja AJ, Opler MG, Greenspoon M, Corcoran CM, 2013 Public stigma associated with psychosis risk syndrome in a college population: implications for peer intervention. *Psychiatric Services*. 64(3):284–8. [PubMed: 23450386]
34. Yang LH, Link BG, Ben-David S, Gill KE, Girgis RR, Brucato G, Wonpat-Borja AJ, Corcoran CM, 2015 Stigma related to labels and symptoms in individuals at clinical high-risk for psychosis. *Schizophrenia research*. 168(1):9–15. [PubMed: 26314731]
35. Yang LH, Crump FM, Ruiz B, Kim B, Blasco D, Ceccolini C, Shah B, Sardana S, DeVlyder J, Corcoran CM (in progress). Qualitative Impacts of being Identified as at a Clinical High Risk State for Psychosis.
36. Yung AR, Yuen HP, Francey SM, McFarlane CA, Hallgren M, McGorry PD, 2003 Psychosis prediction: 12-month follow up of a high-risk (“prodromal”) group. *Schizophrenia Research*. 60, 21–32. [PubMed: 12505135]




Figure 1. Conceptual Model of Hypothesis: Labeling by Others (*Told*) and Self-labeling (*Think*) Processes and Associations with Sense of Self Being Most Affected




Figure 2.
Flowchart of the At-Risk Labeling Module

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1.

Sample Characteristics^a

	Participants (n=148)	
	N (%)	Mean (SD)
Age (in Years)		18.6 (4.2)
Sex- Male	97 (65.6%)	
Site		
Massachusetts	70 (47.3%)	
Maine	47 (31.8%)	
New York	31 (20.9%)	
Received PR Feedback Prior to Stigma Assessment	45 (30.4%)	
Years of education		11.7 (3.1)
Born in US	136 (91.9%)	
Preferred Language-English	138 (93.2%)	
Household Income (dollars/ year)		
Less than \$19,999	20 (13.5%)	
\$20,000-\$39,999	19 (12.8%)	
\$40,000-\$59,999	8 (5.4%)	
\$60,000-\$99,999	19 (12.8%)	
\$100,000 and above	24 (16.2%)	
Don't know, Refused or Missing	58 (39.2%)	
Marital Status-Not married	140 (94.6%)	
Currently Employed (full-time or part time)	43 (29.1%)	
Enrolled as a Student	113 (76.4%)	
Race/Ethnicity		
White	91 (61.5%)	
Black	19 (12.8%)	
Hispanic	20 (13.5%)	
First Nations	3 (2.0%)	
Other ^b	15 (10.2%)	
Family History of Psychosis or Schizophrenia	42 (28.4%)	
Axis-1 Disorders		
1 Axis 1 Disorder	104 (70.3%)	
Depression/MDD	75 (50.7%)	
Anxiety Disorders	64 (43.2%)	
Post-traumatic Stress Disorder	7 (4.7%)	
Attention Deficit/Hyperactivity Disorder	19 (12.8%)	
Bipolar Disorder	17 (11.5%)	
Personality Disorders	1 (0.7%)	
Developmental Disorders	2 (1.4%)	
Substance Abuse Disorder	11 (7.4%)	

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Participants (n=148)		
	N (%)	Mean (SD)
Symptoms		
Total positive		13.6 (4.1)
Total negative		15.0 (6.5)
Total disorganized		7.0 (3.7)
Total general		11.2 (4.1)
Current Social Scale		5.7 (2.1)
Current Role Scale		5.9 (1.5)

Note: Social Scale assessed quantity and quality of age appropriate relationships, and scores ranged from 1 (poor functioning) to 10 (superior functioning). Role scale assessed performance in school, work, or as a homemaker, and scores ranged from 1 (poor functioning) to 10 (superior functioning).

^aCHR symptoms and functioning were assessed by clinician interview; all other responses were assessed via self-report or by interview with a non-clinician.

^bOther' Racial breakdown: Missing 1.4%, East Asian 0.7%, South Asian 1.4%, West/ Central Asia and Middle East 2.0%, Interracial 4.7%.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2A.

Descriptive Statistics for Endorsement of Specific Condition

Variables ^a	Depression	Anxiety	Bipolar	Psychosis	Schizophrenia
Has anyone TOLD ^b you that you were at-risk for [condition]? -Yes	71.6% (106/148)	60.8% (90/148)	28.4% (42/148)	49.3% (73/148)	31.1% (46/148)
Do you THINK ^b you are at-risk for [condition]? -Yes	76.4% (113/148)	78.4% (116/148)	34.5% (51/148)	50.7% (75/148)	39.9% (59/148)
What had the biggest IMPACT ^c on how you see yourself-[condition]? -Yes	35.8% (53/148)	25.7% (38/148)	6.1% (9/148)	16.9% (25/148)	10.8% (16/148)

^aNote: The total “n” for each condition reflects missing values. The “Impact” variable has n<148 because some respondents were not able to identify a single condition which had the greatest impact on their sense of self (n=7).

^bNote: Percentage of endorsed conditions does not add up to 100% because respondents could endorse one or more at-risk condition

^cNote: Percentage of endorsed conditions could add up to 100% because respondents could only endorse one at-risk condition that *most impacted* them (seven participants did not endorse any disorder).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2B:

Descriptive Statistics for Endorsement of Psychosis-Risk Condition

Variables	Frequency Yes to Non-Psychotic Risk ^a (n/N)	Frequency Yes to Psychosis-Risk ^b (n/ N)	p-value ^e
Has anyone TOLD ^c you that you were at-risk for...?	85.1% (126/148)	58.1% (86/148)	<0.001
Do you THINK ^c you are at-risk for...?	91.9% (136/148)	58.9% (87/148)	<0.001
What had the biggest IMPACT ^d on how you see yourself?	67.6% (100/148)	27.7% (41/148)	0.008

^a Includes those who endorsed being at risk for “depression”, “anxiety” or “bipolar”.

^b Includes those who endorsed being at risk for “psychosis” or “schizophrenia”.

^c Note: Percentage of endorsed conditions does not add up to 100% because respondents could endorse one or more at-risk condition

^d Note: Percentage of endorsed conditions could add up to 100% because respondents could only endorse one at-risk condition that *most impacted* them (seven participants did not endorse any disorder).

^e McNemar’s Test

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 3A:

Categorical Analyses between ‘Psychosis-Risk’ Variables

	THINK you were at psychosis-risk		Chi-Square (χ^2)	p-value
	YES	NO		
<i>TOLD you are at psychosis-risk-</i>				
YES	86.0% (74/86)	14.0% (12/86)	63.0	<.001
NO	21.0% (13/62)	79.0% (49/62)		

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 3B.

Categorical analyses between 'told', 'think' and 'most impacted' variables.

	Psychosis-risk had the biggest IMPACT on how you see yourself		Chi-Square (χ^2);	p-value
	YES	NO		
<u>TOLD</u> YOU WERE AT PSYCHOSIS-RISK				
YES	41.9% (36/86)	58.1% (50/86)	20.5	<0.001
NO	8.06% (5/62)	91.9% (57/62)		
<u>THINK</u> YOU ARE AT PSYCHOSIS-RISK				
YES	43.7% (38/87)	56.3% (49/87)	26.9	<0.001
NO	4.9% (3/61)	95.1% (58/61)		

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 3C.

Categorical analyses between 'PR program feedback' and 'told', 'think' and 'most impacted' variables.

PR Program Feedback	TOLD you are at psychosis-risk (Y/N)			THINK you are at psychosis-risk (Y/N)			Psychosis or schizophrenia risk had the biggest IMPACT on how you see yourself (Y/N)		
	Yes	No	p-value ^a	Yes	No	p-value ^a	Yes	No	p-value ^a
Yes	82.2% (37/45)	17.8% (8/45)	<0.001	80.0% (36/45)	20.0% (9/45)	<0.001	33.3% (15/45)	66.7% (30/45)	0.312
No	47.6% (49/103)	52.4% (54/103)		49.5% (51/103)	50.5% (52/103)		25.2% (26/103)	74.5% (77/103)	

^a Chi-square test

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 4.

Logistic Regression Showing Predictors of Being ‘Most Impacted’ by Psychosis Risk’

	Model 1 N=148 AOR (95% CI)	Model 2 N=137 ^d AOR (95% CI)	Model 3 N=137 ^d AOR (95% CI)
Told at Psychosis Risk			
No	<i>Ref</i>	<i>Ref</i>	<i>Ref</i>
Yes	8.7 (3.1, 24.8)^c	10.6 (3.3, 33.9)^c	4.0 (1.1, 15.0)^a
Think at Psychosis Risk			
No	--	--	<i>Ref</i>
Yes			8.8 (2.0, 39.1)^b
Received PR Feedback^e			
No	<i>Ref</i>	<i>Ref</i>	<i>Ref</i>
Yes	0.8 (0.4, 1.9)	1.1 (0.3, 3.6)	0.8 (0.2, 2.7)
Family History of Psychosis/Schizophrenia			
No	--	<i>Ref</i>	<i>Ref</i>
Yes		0.6 (0.2, 1.7)	0.6 (0.2, 1.8)
Age (Years)	--	1.0 (0.9, 1.1)	1.0 (0.8, 1.1)
Sex			
Female	--	<i>Ref</i>	<i>Ref</i>
Male		2.5 (0.9, 6.7)	2.6 (0.9, 7.4)
Race/Ethnicity			
Non-White	--	<i>Ref</i>	<i>Ref</i>
White		1.0 (0.4, 2.6)	0.7 (0.2, 2.0)
SIPS Symptoms			
Positive		1.1 (1.0, 1.3)	1.1 (0.9, 1.3)
Negative		1.0 (0.9, 1.1)	1.0 (0.9, 1.1)
Disorganized		0.9 (0.7, 1.0)	0.9 (0.7, 1.0)
General		1.0 (0.8, 1.1)	0.9 (0.8, 1.1)

Note. OR=Crude Odds Ratio; AOR=Adjusted Odds Ratio; CI=Confidence Interval; Ref=Reference Group; White=non-Hispanic White

Statistically significant at

^a p<0.05,

^b p<0.01,

^c p<0.0001

^d 11 participants were excluded from Models 2 and 3 due to missing information on family history of psychosis (n=5), racial/ethnicity information (n=2) and SIPS data (n=4).

^e Mean time since PR program feedback for NY site participants= 10.2 weeks (*SD*= 9.3 weeks)